Pharmidex
Saravanan Masilamani is a Scientist at Pharmidex since May 2023, previously serving as Study Director at The Griffin Institute from August 2022 to May 2023. Saravanan has extensive experience at the International Institute of Biotechnology and Toxicology, where work spanned from June 2008 to December 2021, focusing on GLP-compliant studies involving Honeybee, Earthworm, and Silkworm Toxicity Tests, as well as Beneficial Arthropod studies and preparation of necessary SOPs. Educational credentials include an M.Phil in Zoology and a Master's degree in Zoology from the University of Madras, as well as a Bachelor's degree in Zoology from the same institution.
This person is not in any teams
This person is not in any offices
Pharmidex
Pharmidex is an AAALAC-accredited, UK-based CRO founded in 2002. We provide high-quality, cost-effective, flexible and rapid solutions in drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP/GLP/GCP), toxicology (non-GLP/GLP), histology, clinical chemistry, hematology, and in vitro ADME. Pharmidex also offers in silico modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune, and metabolic disease programs. We work with over 250 global clients, including medical charities, academic groups, biotech, and pharma, and have undertaken over 15,000 studies. In addition to our fee-for-service offering, Pharmidex actively seeks collaboration opportunities in grant-funded projects. To date, we have successfully participated in over 30 collaborative grant-funded projects, partnering with more than 167 global collaborators.